Blue Trust Inc. Raises Holdings in 10x Genomics $TXG

Blue Trust Inc. increased its position in shares of 10x Genomics (NASDAQ:TXG) by 48.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,894 shares of the company’s stock after purchasing an additional 1,590 shares during the quarter. Blue Trust Inc.’s holdings in 10x Genomics were worth $57,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC increased its position in shares of 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock worth $31,000 after purchasing an additional 1,614 shares in the last quarter. Signaturefd LLC increased its position in shares of 10x Genomics by 134.3% during the first quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock worth $37,000 after purchasing an additional 2,409 shares in the last quarter. Whittier Trust Co. purchased a new stake in shares of 10x Genomics during the first quarter worth approximately $41,000. PNC Financial Services Group Inc. increased its position in shares of 10x Genomics by 153.6% during the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company’s stock worth $45,000 after purchasing an additional 3,119 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of 10x Genomics by 314.5% during the first quarter. US Bancorp DE now owns 5,973 shares of the company’s stock worth $52,000 after purchasing an additional 4,532 shares in the last quarter. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $103,231.94. Following the transaction, the insider owned 440,888 shares of the company’s stock, valued at approximately $6,079,845.52. This represents a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Adam Taich sold 22,315 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the transaction, the chief financial officer directly owned 309,273 shares in the company, valued at approximately $4,264,874.67. The trade was a 6.73% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,149 shares of company stock valued at $539,865. Corporate insiders own 9.39% of the company’s stock.

10x Genomics Stock Down 4.4%

Shares of 10x Genomics stock opened at $11.83 on Friday. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $18.21. The business’s fifty day simple moving average is $12.87 and its 200-day simple moving average is $11.16. The firm has a market cap of $1.47 billion, a PE ratio of -16.90 and a beta of 2.05.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. During the same quarter in the prior year, the company posted ($0.32) EPS. The company’s quarterly revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, equities analysts expect that 10x Genomics will post -1.43 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on TXG shares. Barclays reissued an “overweight” rating and set a $15.00 price objective (up previously from $13.00) on shares of 10x Genomics in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on 10x Genomics and gave the stock a “hold” rating in a research note on Friday, August 8th. Bank of America boosted their price objective on 10x Genomics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Thursday, June 26th. Zacks Research raised 10x Genomics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Finally, Canaccord Genuity Group set a $16.00 price objective on 10x Genomics in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $13.65.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.